B-Cell Epitopes-Based Chimeric Protein from SARS-CoV-2 N and S Proteins Is Recognized by Specific Antibodies in Serum and Urine Samples from Patients
Authors:
- Fernanda F. RamosFRFernanda F. Ramos
- Isabela A. G. PereiraIPIsabela A. G. Pereira
- Mariana M. CardosoMCMariana M. Cardoso
- Raquel S. BandeiraRBRaquel S. Bandeira
- Daniela P. LageDLDaniela P. Lage
- Rahisa ScusselRSRahisa Scussel
- Rafaela S. AnastacioRARafaela S. Anastacio
- Victor G. FreireVFVictor G. Freire
- Marina F. N. MeloMMMarina F. N. Melo
- Joao A. Oliveira-Da-SilvaJOJoao A. Oliveira-Da-Silva
- Vivian T. MartinsVMVivian T. Martins
- Grasiele S. V. TavaresGTGrasiele S. V. Tavares
Open Access
Abstract
The impact of the COVID-19 pandemic caused by the SARS-CoV-2 virus underscored the crucial role of laboratorial tests as a strategy to control the disease, mainly to indicate the presence of specific antibodies in human samples from infected patients. Therefore, suitable recombinant antigens are relevant for the development of reliable tests, and so far, single recombinant proteins have been used. In this context, B-cell epitopes-based chimeric proteins can be an alternative to obtain tests with high accuracy through easier and cheaper production. The present study used bioinformatics tools to select specific B-cell epitopes from the spike (S) and the nucleocapsid (N) proteins from the SARS-CoV-2 virus, aiming to produce a novel recombinant chimeric antigen (N4S11-SC2). Eleven S and four N-derived B-cell epitopes were predicted and used to construct the N4S11-SC2 protein, which was analyzed in a recombinant format against serum and urine samples, by means of an in house-ELISA. Specific antibodies were detected in the serum and urine samples of COVID-19 patients, which were previously confirmed by qRT-PCR. Results showed that N4S11-SC2 presented 83.7% sensitivity and 100% specificity when using sera samples, and 91.1% sensitivity and 100% specificity using urine samples. Comparable findings were achieved with paired urine samples when compared to N and S recombinant proteins expressed in prokaryotic systems. However, better results were reached for N4S11-SC2 in comparison to the S recombinant protein when using paired serum samples. Anti-N4S11-SC2 antibodies were not clearly identified in Janssen Ad26.COV2.S COVID-19-vaccinated subjects, using serum or paired urine samples. In conclusion, this study presents a new chimeric recombinant antigen expressed in a prokaryotic system that could be considered as an alternative diagnostic marker for the SARS-CoV-2 infection, with the potential benefits to be used on serum or urine from infected patients.Keywords
Funding Information
- Secretaria de Educação Superior do Ministério da Educação (SESU/MEC) (04/2020, APQ-02167-21)
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (04/2020, APQ-02167-21)
- Brazilian agencies Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (04/2020, APQ-02167-21)
This publication has 30 references indexed in Scilit:
- Immunologic Testing for SARS-CoV-2 Infection from the Antigen PerspectiveJournal of Clinical Microbiology, 2021
- In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19Scientific Reports, 2021
- Systematic evaluation of IgG responses to SARS-CoV-2 spike protein-derived peptides for monitoring COVID-19 patientsCellular & Molecular Immunology, 2021
- SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein RegionVaccines, 2021
- Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine TargetsFrontiers in Immunology, 2020
- A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populationsScience Translational Medicine, 2020
- Design of multi-epitope vaccine candidate against SARS-CoV-2: ain-silicostudyJournal of Biomolecular Structure and Dynamics, 2020
- Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2Journal of Clinical Microbiology, 2020
- Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus InfectionJournal of Virology, 2014
- The Coronavirus Nucleocapsid Protein Is Dynamically Associated with the Replication-Transcription ComplexesJournal of Virology, 2010